Mr. Shane Madden reports

HYDREIGHT TECHNOLOGIES ENTERS THE AT-HOME STI TESTING MARKET WITH EXCLUSIVE DISTRIBUTION AND 50,000 PRE-ORDERS

Hydreight Technologies Inc. has entered the rapidly expanding at-home sexually transmitted infection (STI) prescreening market through an exclusive distribution agreement with Health Screen Collective (HSC).

Under the agreement, Hydreight will serve as the exclusive distributor of HSC's at-home STI prescreen testing kits across its national platform. The company has already secured approximately 50,000 preorders, with deliveries expected to begin in early 2026.

A widespread, underdiagnosed public health reality

Sexually transmitted infections represent one of the most prevalent and underdiagnosed health care challenges in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately one in five people in the United States is living with an STI at any given time, with tens of millions of new infections occurring annually. Despite this prevalence, a significant portion of infections remain undiagnosed due to stigma, inconvenience, cost and long wait times associated with traditional clinic-based testing.

Globally, the World Health Organization (WHO) estimates that more than one million curable STIs are acquired every day, underscoring the scale of the issue and the growing need for accessible, private screening solutions.

Testing in minutes, not days

HSC's at-home STI prescreen testing kits are designed to deliver results in minutes rather than days, enabling faster awareness and earlier engagement with care. Using validated lateral-flow immunoassay technology, the kits allow individuals to collect samples privately at home through clear, step-by-step instructions, eliminating the need for clinic visits or laboratory processing delays at the initial screening stage.

Depending on the selected panel, the kits provide prescreening for multiple common infections, including:

• Chlamydia trachomatis;
• Neisseria gonorrhoeae;
• Trichomonas vaginalis;
• Mycoplasma genitalium;
• Candida albicans;
• Gardnerella vaginalis.

This approach addresses one of the most critical gaps in STI care today: speed matters. Faster screening enables earlier clinical decisions, reduces transmission risk and improves patient follow-through.

Accuracy and sensitivity highlights

According to product validation data and instructions for use provided by Health Screen Collective, the at-home STI prescreen testing kits demonstrate high levels of sensitivity, specificity and overall accuracy across multiple screened pathogens. The tests utilize validated lateral-flow immunoassay technology and are designed to detect clinically relevant infection markers with performance characteristics comparable with commonly used laboratory-based screening methods for initial detection. These accuracy metrics support the kits' role as reliable prescreening tools, enabling faster identification of potential infections and earlier clinical follow-up when integrated into licensed care pathways.

From prescreening to end-to-end care

The kits are positioned as prescreening tools, designed to help individuals identify potential infections earlier and take appropriate next steps. When integrated into Hydreight's platform, users can move seamlessly from prescreening to licensed medical review, confirmatory testing, clinical consultation and treatment co-ordination, where clinically appropriate.

This integrated workflow transforms at-home testing from a stand-alone product into a connected digital health care experience, addressing both access and continuity of care.

Why this matters for Hydreight

STI screening is a high-frequency, repeat-use health care category, driven by public health guidelines and continuing patient behaviour. The combination of recurring screening needs, rapid results and integrated clinical follow-up aligns directly with Hydreight's platform-first strategy.

The initial 50,000 preorders reflect early demand from enterprise partners, health care operators, and distribution channels seeking scalable, at-home prescreening solutions that can be deployed nationally and embedded into broader digital care workflows.

"This category highlights exactly why our platform exists," said Shane Madden, chief executive officer of Hydreight. "When you combine fast, at-home screening with licensed providers and national fulfilment, you remove friction from a category that desperately needs it. That's where real health care transformation happens."

Platform leverage, not a one-off product

Hydreight views at-home STI prescreening as another example of how its infrastructure can be leveraged to rapidly launch and scale health care services across large, fragmented markets. Rather than operating as a single product, the company expects this offering to drive repeat engagement, downstream clinical services, pharmacy fulfilment and long-term platform utilization.

About Hydreight Technologies Inc.

Hydreight Technologies is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3,000 nurses, over 300 doctors and a pharmacy network through its doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enables licensed health care professionals to provide services directly to patients at home or at offices or hotels. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians and other licensed health care professionals. The Hydreight platform allows health care professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne -- direct-to-consumer platform

Developed in partnership with Victory Square Technologies, Hydreight Technologies launched the VSDHOne (read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the on-line health care space compliantly. This platform will help all businesses to launch a direct-to-consumer health care brand in a matter of days in all 50 states. Compliant offerings include GLP-1s, peptides, personalized health care treatments, sermorelin, testosterone replacement therapy (TRT), hair loss, skin care, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete and modular end-to-end solution for businesses looking to launch direct-to-consumer health care brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the on-line health care space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

We seek Safe Harbor.